Longevity Health (NASDAQ:XAGE) Trading Up 11.7% – Here’s Why

Longevity Health Holdings, Inc. (NASDAQ:XAGE) shot up 11.7% on Tuesday . The company traded as high as $0.6499 and last traded at $0.6499. 809 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 762,144 shares. The stock had previously closed at $0.5820.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Longevity Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th.

Longevity Health Stock Performance

The company has a market cap of $1.16 million, a price-to-earnings ratio of -0.09 and a beta of 0.34. The firm’s 50-day moving average price is $0.97.

Longevity Health (NASDAQ:XAGE) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.56) earnings per share for the quarter. The company had revenue of $0.50 million for the quarter.

Hedge Funds Weigh In On Longevity Health

A hedge fund recently bought a new stake in Longevity Health stock. Bank of Montreal Can purchased a new position in shares of Longevity Health Holdings, Inc. (NASDAQ:XAGE) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,000 shares of the company’s stock, valued at approximately $30,000. Bank of Montreal Can owned approximately 1.20% of Longevity Health as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing.